Springworks Therapeutics Inc (SWTX) - News Archive

European Commission Grants Conditional Approval of EZMEKLY (mirdametinib) for Treatment of Neurofibromatosis Type 1-Associated Peripheral Nerve Sheath Tumors (NF1-PN)In a groundbreaking development for patients sufferin...

Neurofibromatosis type 1 (NF1) is a neurogenetic disorder characterized by the development of multiple tumors, most notably plexiform neurofibromas (NF1-PN). These tumors often lead to significant morbidity, impacting p...

As the field of oncology continues to advance, the importance of long-term efficacy and safety data remains paramount in the development of novel therapeutics. SpringWorks Therapeutics Inc. (NASDAQ: SWTX) has made signi...

Recent advancements in the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) have centered around SpringWorks Therapeutics investigational MEK inhibitor, mirdametinib. This article provid...

SpringWorks Therapeutics Submits New Drug Application to FDA for Mirdametinib in Treatment of Neurofibromatosis Type 1-Plexiform NeurofibromasSTAMFORD, Conn., July 01, 2024 - SpringWorks Therapeutics, a leading biopharm...

SpringWorks Therapeutics, a pioneering biopharmaceutical company pursuing novel treatment modalities with transformational potential, has announced that their abstracts have been accepted for presentation at the much-an...

SpringWorks Therapeutics Initiates New Drug Application for Mirdametinib for the Treatment of Neurofibromatosis Type 1-Associated Plexiform NeurofibromasSpringWorks Therapeutics, a leading biopharmaceutical company, has...

In a recent announcement, SpringWorks Therapeutics revealed that the European Medicines Agency (EMA) has validated the marketing authorization application for Nirogacestat, a potential breakthrough treatment for adults...

SpringWorks Therapeutics Raises $316.25 Million in Successful Public OfferingSTAMFORD, Conn., Dec. 08, 2023 - SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a leading biopharmaceutical company specializing in severe rar...

SpringWorks Therapeutics Announces Pricing and Details of Public Offering, Set to Raise Approximately $275 MillionIn a recent press release, SpringWorks Therapeutics, a leading biopharmaceutical company focused on sever...

SpringWorks Therapeutics, a leading biopharmaceutical company focusing on severe rare diseases and cancer, has recently announced its plan to commence an underwritten public offering of $250.0 million worth of shares of...